VRDN Compensation

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published August 04, 2025 at 11:00 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 181,450 shares of the company’s common stock to 4 new employees (th

Related Questions

How many shares will be issued under the grant and what percentage of the total outstanding shares does that represent? Is there any indication that this grant is part of a larger equity incentive plan or a one‑off award? What are the exercise prices and vesting schedules for the granted stock options? Who are the four new employees receiving the options and what roles will they fill within the company? What are the potential short‑term and medium‑term impacts on VRDN’s stock price and trading volume? How does the Nasdaq Listing Rule 5635(c)(4) affect the timing or reporting of this grant? Is the 181,450‑share grant consistent with the company’s overall compensation philosophy and future hiring plans? How might the grant affect the company's cash flow, tax expense, and earnings per share? How does this compensation grant compare to prior issuances or similar grants at peer biotech companies? What is the rationale behind using non‑qualified stock options rather than other equity awards? Will the issuance be disclosed in the upcoming 10‑K or 10‑Q filing, and what regulatory filings are required? What is the estimated dilution impact on existing shareholders from the 181,450 share option grant?